Revenue for the quarter will provide a good indication of how profitable Spontan will be. Im assuming at least a few thousand people will get a prescription so it will be very interesting to see the numbers. Also, if LTR makes a deal with a big pharma player within the next year it won’t just be individuals buying in, institutions will want a piece too. Given how the price has tripled from positive trial results and early access, who’s to say it won’t triple again alongside all of this news flow expected in the coming months? $5 by July next year is a conservative guess.
Revenue for the quarter will provide a good indication of how...
-
- There are more pages in this discussion • 16 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add LTP (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.72 |
Change
-0.025(1.44%) |
Mkt cap ! $145.4M | |||
| Open | High | Low | Value | Volume |
| $1.74 | $1.82 | $1.68 | $1.112M | 631.7K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 495 | $1.72 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.74 | 5000 | 1 |
View Market Depth
| Last trade - 16.10pm 13/09/2024 (20 minute delay) ? |
| LTP (ASX) Chart |